Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: Targeting the NAT10-HDAC4 positive feedback loop counteracts immunosuppression in breast cancer

doi: 10.1186/s13046-025-03638-7

Figure Lengend Snippet: Inhibition of NAT10 enhances the efficacy of anti–PD-L1 therapy in vivo . A Schematic diagram of the tumor model and treatment schedule with anti-PD-L1 administration. B–D Representative images ( B ), tumor growth curves ( C ), and tumor weights ( D ) of mouse 4T1 tumors from shNC, shNAT10, anti-PD-L1, or the combination of shNAT10 and anti-PD-L1 ( n = 6). E-F Representative mIF images of mouse tumor tissues showing staining for T cells ( E ), Tregs ( F ), and MDSCs ( F ) (scale bar, 20 μm). G - H ELISA analysis of GzmB (G) and IFN-γ (H) levels in the serum of mice from different groups. I Representative IHC staining of PD-L1, CD8, and GzmB in breast cancer tissues ( n = 220), with statistical analysis of staining intensity (scale bar, 200 μm). J Correlation of PD-L1 and CD8, and PD-L1 and GzmB protein levels in breast cancer tissues ( n = 220) assessed by IHC. All data are presented as mean ± SD. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001

Article Snippet: In the CD8+ T cell depletion assay, mice were administered anti-Mouse CD8α antibody (Clone 2.43) (MedChemExpress, #HY-P990790, China) intraperitoneally at a dose of 300 μg daily for three consecutive days.

Techniques: Inhibition, In Vivo, Staining, Enzyme-linked Immunosorbent Assay, Immunohistochemistry

Journal: The Journal of Clinical Investigation

Article Title: Intranasal DC-targeting vaccine booster elicits durable and cross-clade protective immunity against sarbecoviruses in mice

doi: 10.1172/JCI195784

Figure Lengend Snippet: ( A ) The 5- to 6-week-old BALB/c mice were immunized with original Comirnaty mRNA vaccine as described in Figure 1. At 3 months after the second immunization dose, mice were boosted with either BC mRNA vaccine (0.05 μg; i.m.) or Clec9A OMNI (4 μg Clec9A XBB + 1 μg Clec9A CoV1 adjuvanted with 50 μg poly I:C; i.n.). ( B – E ) Spleen, BM from femur/tibia, and lung were harvested at 6 months after boost. ( B and C ) Percentages of AIM + Tfh ( B ) and RBD + GC ( C ) B cells in spleen and lung were determined by flow cytometry. ( D and E ) Frequency of BM RBD-specific IgG + LLPCs and non-LLPCs (normalized to total IgG) ( D ) and pooled lung RBD-specific IgG + and IgA + LLPCs and non-LLPCs (normalized to total IgG and IgA) ( E ) was determined by B cell ELISpot. ( F – J ) Spleen, lung, and NALT were harvested at 4 months after boost. ( F – H ) Frequencies of IFN-γ–, IL-2–, and/or TNF-α–secreting splenocytes ( F ), lung cells ( G ), and pooled NALT cells ( H ) were determined by FluoroSpot upon restimulation with ancestral SARS-CoV-2, XBB.1.5, JN.1, RaTG13, Gx-P5L, SARS-CoV-1, and WIV-1 RBD peptides. ( I and J ) Percentages of lung ( I ) and NALT ( J ) CD4 + and CD8 + T RM cells were determined by flow cytometry. Data in B – J are from 1 representative experiment performed twice with similar results; n = 4–5 per group/experiment. Symbols in B – E , I , and J represent individual animals, and data shown in B – J are means. Statistical analysis: nonparametric 2-tailed Mann-Whitney test ( D ) and Kruskal-Wallis test ( B , C , F , G , I , and J ) with Dunn’s multiple-comparison test. * P < 0.05, ** P < 0.01. Asterisk colors in F and G represent statistical significance between corresponding groups.

Article Snippet: For analysis of CD4 + and CD8 + T cell responses, CD4 + - and CD8 + -enriched single-cell suspensions were prepared using mouse CD4 (L3T4) (Miltenyi Biotec, 130-117-043) and CD8α (Ly-2) (Miltenyi Biotec, 130-117-044) microbeads, according to the manufacturer’s protocol.

Techniques: Flow Cytometry, Enzyme-linked Immunospot, MANN-WHITNEY, Comparison